Development of hyperthyroidism during long term interferon therapy in a patient with chronic myelogenous leukemia: case report.
In this case report a patient with thyroid dysfunction who received chronic treatment with interferon-alpha (INF-alpha) following a diagnosis of chronic myelogenous leukemia (CML) is described. Generally INF-alpha induced dysthyroidism develops in the earlier phase of INF-alpha treatment. This is a case report of thyroid dysfunction which occurred 4 years after the patient began to receive INF-alpha administration. In addition, INF-alpha was administered to this patient for a longer period than those reported in the literature.
Ozet
A
A
Department of Medical Oncology, Gülhane Military Academy, Ankara-Turkey.
Ozet
G
G
Calişkaner
Z
Z
Kömürcü
S
S
Oztürk
B
B
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged
D000970:Antineoplastic Agents; D016898:Interferon-alpha